2248127-86-6
Chemical Structure
PM54-1
- CAS No.: 2248127-86-6
- Formula:C41H43N3O11S
- Molecular Weight:785.86
InChIKey: RFAHKSOPHUEQBC-LDLGASKLSA-N
SMILES: CC(C1=C2OCO1)=C(OC(C)=O)C3=C2[C@H](CO4)N([C@@H](O)C5N(C)C6C7=C(C=C(C)C(OC)=C7O)C5)[C@@]6([H])[C@@H]3SC[C@](C8=C9C%10=CC=CC=C%10O8)(N[C@H](CO)C9)C4=O
Biological Activity: PM54 is an antitumor agent with activity across multiple cancer types. PM54 acts as a transcription and WNT/β-catenin signaling pathway inhibitor. PM54 suppresses oncogenic transcriptional programs, and key malignant pathways, while inducing DNA double-strand breaks, S-phase cell cycle arrest and apoptosis. PM54 enhances innate immune recognition, remodels the tumor microenvironment. PM54 exhibits antitumor activity as monotherapy or in combination in xenograft models. PM54 is applicable to research on various cancers and advanced solid tumors[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PM54-1 | PM54 is an antitumor agent with activity across multiple cancer types. PM54 acts as a transcription and WNT/β-catenin signaling pathway inhibitor. PM54 suppresses oncogenic transcriptional programs, and key malignant pathways, while inducing DNA double-strand breaks, S-phase cell cycle arrest and apoptosis. PM54 enhances innate immune recognition, remodels the tumor microenvironment. PM54 exhibits antitumor activity as monotherapy or in combination in xenograft models. PM54 is applicable to research on various cancers and advanced solid tumors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Fernández-Miranda I, et al. PM54 targets oncogenic transcriptional networks across multiple cancer types. Cancer Res. 2026;86(7 Suppl):Abstract 2981.
- [2]. Gutierrez Alvarez FJ, et al. PM54 suppresses WNT/β-catenin signaling and synergizes with chemotherapy in gastric cancer models. Cancer Res. 2026;86(7 Suppl):Abstract 5754.
- [3]. Gorgels D, et al. The next generation transcriptional inhibitor PM54 demonstrates strong antitumor activity in patient-derived xenograft models of soft tissue sarcoma. Cancer Res. 2025;85(8 Suppl 1):Abstract 6858.
Keywords
